Abstract: A system and method is disclosed for solar tracking and controlling an angular position of a photovoltaic power system. The solar tracking system includes an imaging device for capturing images of the sky; a solar position data generating module; and a control system comprising a neural network. The neural network has multiple convolutional layers to generate a first output associated with the images, and a solar position data module. A first dense layer module receives the solar position data and generates a second output. A second dense layer module receives the first output and the second output and generates a concatenated data sequence. A processor is programmed to generate a multi-planar irradiance signal (MPIS) in response to the concatenated data sequence, and determine an angular position of the PV power system and adjust the angular position in response to an angle of maximum irradiance.

Abstract: Disclosed are systems, methods, and non-transitory computer-readable storage media for managing project tasks using content items. A user can create tasks within a content item. The tasks can be assigned to users and/or be assigned due dates. The content item can be shared with other users such that updates to the content item (e.g., updates to the tasks) can cause sending notifications to users associated with the content item. When a task in the content item is updated, all members of the project can be notified of the updated status of the task. A task list for a project can be created that aggregates tasks from multiple content items associated with the project. Tasks can be organized in the task list according to the content item the task was created in. Updates to tasks in the task list can cause corresponding updates to the tasks in the content items.

Abstract: This disclosure describes techniques for identifying an application (e.g., accessing application) that is attempting to access a resource. In some examples, access may be managed by an authentication service. When an access request is received at the authentication service from an application on a client device, the authentication service may ask the application to communicate with an identification agent on the client device. The identification agent may perform one or more tests to discover the identity of the application. In some cases, the identification agent may send the identity of the application to the authentication service. The authentication service may then allow or deny access by the accessing application to the resource based at least in part on the discovered identity.

Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. GDC-6036) and an PI3K-inhibitor (e.g. inavolisib) and methods of using such combination therapies.

Abstract: Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).

Abstract: A computer-implemented method for managing a contact center one or more processors in a management network (a) receiving, from an end-user network, data associated with a plurality of agent instances servicing incoming communications for the contact center, wherein the contact center, the end-user network, and the management network are associated with the enterprise; (b) determining, based on a specification of a logical directive, an operation to be performed in relation to the plurality of agent instances, the specification of the logical directive having at least one condition that, if satisfied by the received data associated with the plurality of agent instances servicing the incoming communications for the contact center, defines the operation to be performed; and (c) providing, to one or more servers, the determined operation to be performed, wherein the operation includes making a modification relating to (i) at least one of the plurality of agent instances and/or (ii) the servicing of the incoming c

Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Abstract: A method includes (a) receiving and storing interaction time data associated with processes of a communication distributor server for an end-user network having an associated contact center with agent instances; (b) determining whether a trigger specified in a first logical directive is initiated; (c) upon determining that the trigger specified in the first logical directive is initiated, determining whether a metric related to the customer communications with the end-user network satisfies the condition in the first logical directive; and (d) upon determining that the metric related to the customer communications with the end-user network satisfies the condition in the first logical directive, providing the operation to at least one of the end-user network or the communication distributor server.

Abstract: Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+/HER2?) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.

Abstract: A method includes (a) receiving and storing interaction time data associated with processes of a communication distributor server for an end-user network having an associated contact center with agent instances; (b) determining whether a trigger specified in a first logical directive is initiated; (c) upon determining that the trigger specified in the first logical directive is initiated, determining whether a metric related to the customer communications with the end-user network satisfies the condition in the first logical directive; and (d) upon determining that the metric related to the customer communications with the end-user network satisfies the condition in the first logical directive, providing the operation to at least one of the end-user network or the communication distributor server.

Abstract: Systems, computing devices, and methods for indicating a geographic location of transportation for a user are disclosed. According to an aspect, a method includes determining an approximate time when a user is expected to use a mode of transportation. The method also includes determining an estimated time to travel from a current geographic location of the user to a current geographic location of the mode of transportation. Further, the method includes presenting, via a computing device of the user, a message at a time based on the determined approximate time and the determined estimated time.

Abstract: This disclosure describes techniques for identifying an application (e.g., accessing application) that is attempting to access a resource. In some examples, access may be managed by an authentication service. When an access request is received at the authentication service from an application on a client device, the authentication service may ask the application to communicate with an identification agent on the client device. The identification agent may perform one or more tests to discover the identity of the application. In some cases, the identification agent may send the identity of the application to the authentication service. The authentication service may then allow or deny access by the accessing application to the resource based at least in part on the discovered identity.

Abstract: Methods, devices and program products are provided for utilizing one or more processors to receive a request from a client device for a network responsive resource. The network responsive resource includes a substitute scripted component. The methods, devices and program products determine whether to implement load sharing based on utilization information indicative of a load and build the network responsive resource with a client-side scripted component as the substitute scripted component.

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Abstract: A system is provided for generating a custom hair dye formulation to be dispensed into a single customer container for a particular customer. The system establishes a connection with a user device of the particular customer over a network, receives a selection of a preferred type of expertise of a colorist, determines an available colorist that corresponds to the preferred type of expertise, establishes a video communication session between the particular customer and a colorist device of the determined colorist, causes display of a customer interface to the customer, causes display of a colorist interface to the colorist device, and transmits the generated custom hair dye formulation to a fill site, via the network.

Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1) and an EGFR-inhibitor and methods of using such combination therapies.

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).

Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.